These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

746 related articles for article (PubMed ID: 22690748)

  • 1. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
    Richter JM; Kushkuley S; Barrett JA; Oster G
    Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ulcerative proctitis: a review of pharmacotherapy and management.
    Lakatos PL; Lakatos L
    Expert Opin Pharmacother; 2008 Apr; 9(5):741-9. PubMed ID: 18345952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
    Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications.
    Richter JM; Arshi NK; Oster G
    Can J Gastroenterol Hepatol; 2016; 2016():6928710. PubMed ID: 27446860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
    Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical therapy is underused in patients with ulcerative colitis.
    Seibold F; Fournier N; Beglinger C; Mottet C; Pittet V; Rogler G;
    J Crohns Colitis; 2014 Jan; 8(1):56-63. PubMed ID: 23566922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study.
    Watanabe M; Nishino H; Sameshima Y; Ota A; Nakamura S; Hibi T
    Aliment Pharmacol Ther; 2013 Aug; 38(3):264-73. PubMed ID: 23734840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
    Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
    Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
    Cohen RD; Woseth DM; Thisted RA; Hanauer SB
    Am J Gastroenterol; 2000 May; 95(5):1263-76. PubMed ID: 10811338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository.
    Kato S; Ishibashi A; Kani K; Yakabi K
    Digestion; 2018; 97(1):59-63. PubMed ID: 29393142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
    Bosworth BP; Sandborn WJ; Rubin DT; Harper JR
    Inflamm Bowel Dis; 2016 Aug; 22(8):1881-6. PubMed ID: 27416045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.
    Yamamoto T; Shimoyama T; Matsumoto K
    Aliment Pharmacol Ther; 2015 Sep; 42(5):549-58. PubMed ID: 26140337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.
    Cortot A; Maetz D; Degoutte E; Delette O; Meunier P; Tan G; Cazals JB; Dewit O; Hebuterne X; Beorchia S; Grunberg B; Leprince E; D'Haens G; Forestier S; Idier I; Lémann M
    Am J Gastroenterol; 2008 Dec; 103(12):3106-14. PubMed ID: 19086960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
    Solomon D; Yarlas A; Hodgkins P; Karlstadt R; Yen L; Kane S
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1386-96. PubMed ID: 22536781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug therapy for ulcerative colitis: salazosulfapyridine and 5-ASA].
    Jo Y; Matsumoto T; Iida M
    Nihon Rinsho; 2005 May; 63(5):820-4. PubMed ID: 15881176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination of rectal beclomethasone diproprionate and mesalazine in ulcerative proctitis.
    Guslandi M; Giollo P; Testoni PA
    Scand J Gastroenterol; 2008; 43(5):639-40. PubMed ID: 18415762
    [No Abstract]   [Full Text] [Related]  

  • 17. Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis.
    Kruis W; Neshta V; Pesegova M; Alekseeva O; Andreev P; Datsenko O; Levchenko O; Abdulkhakov S; Lozynskyy Y; Mostovoy Y; Soloviev K; Dorofeyev AE; Vieth M; Stiess M; Greinwald R; Mohrbacher R; Siegmund B
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):98-106.e4. PubMed ID: 29702300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials.
    Regueiro M; Loftus EV; Steinhart AH; Cohen RD
    Inflamm Bowel Dis; 2006 Oct; 12(10):979-94. PubMed ID: 17012969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
    Sandborn WJ; Hanauer S; Lichtenstein GR; Safdi M; Edeline M; Scott Harris M
    Aliment Pharmacol Ther; 2011 Oct; 34(7):747-56. PubMed ID: 21848857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group.
    d'Albasio G; Paoluzi P; Campieri M; Bianchi Porro G; Pera A; Prantera C; Sturniolo GC; Miglioli M
    Am J Gastroenterol; 1998 May; 93(5):799-803. PubMed ID: 9625131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.